García Marchena, NuriaPizarro, NievesMartínez Huélamos, MiriamPavón Carrasco, Francisco JavierRequena-Ocaña, NereaAraos, PedroSilva-Peña, DanielSuárez, JuanSantín, Luis Javierde la Torre, RafaelSerrano, AntoniaFlores-López, MaríaRodríguez De Fonseca, Fernando Antonio2024-01-252024-01-252020-10-1310.1038/s41598-020-74155-0https://hdl.handle.net/20.500.14352/95328Lysophosphatidic acid (LPA) species are bioactive lipids participating in neurodevelopmental processes. The aim was to investigate whether the relevant species of LPA were associated with clinical features of alcohol addiction. A total of 55 abstinent alcohol use disorder (AUD) patients were compared with 34 age/sex/body mass index-matched controls. Concentrations of total LPA and 16:0-LPA, 18:0-LPA, 18:1-LPA, 18:2-LPA and 20:4-LPA species were quantifed and correlated with neuroplasticity-associated growth factors including brain derived neurotrophic factor (BDNF), insulinlike growth factor-1 (IGF-1) and IGF-2, and neurotrophin-3 (NT-3). AUD patients showed dysexecutive syndrome (22.4%) and memory impairment (32.6%). Total LPA, 16:0-LPA, 18:0-LPA and 18:1-LPA concentrations, were decreased in the AUD group compared to control group. Total LPA, 16:0-LPA, 18:2-LPA and 20:4-LPA concentrations were decreased in men compared to women. Frontal lobe functions correlated with plasma LPA species. Alcohol-cognitive impairments could be related with the deregulation of the LPA species, especially in 16:0-LPA, 18:1-LPA and 20:4-LPA. Concentrations of BDNF correlated with total LPA, 18:2-LPA and 20:4-LPA species. The relation between LPA species and BDNF is interesting in plasticity and neurogenesis functions, their involvement in AUD might serve as a biomarker of cognitive impairment.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/journal article2045-2322open accessCiencias Biomédicas32 Ciencias Médicas